Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

Jun 2022 | From Akero Therapeutics

Efruxifermin (EFX), a long-acting FGF21 analog as a therapy for NASH

Tim Rolph Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease, and Therapies

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment significantly reduced markers of collagen synthesis and fibrosis and normalized levels of Pro-C3 in patients with livery fibrosis associated with NASH

Erik J Tillman, Louben Dorval, Reshma Shringarpure, Erica Fong, Brittany de Temple, Andrew Cheng, Stephen A Harrison, Kitty Yale, Tim Rolph Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease, and Therapies

Nov 2021 | From Akero Therapeutics

Characterization of Histologic Patterns of Improvement Following Treatment With Efruxifermin (EFX) in NASH Patients With Fibrosis

Behling, C. et al. The Liver Meeting 2021 (AASLD)

Nov 2021 | From Akero Therapeutics

Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats

Tillman, E. Et al. The British Journal of Pharmacology

Jul 2021 | FROM AKERO THERAPEUTICS

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Harrison, S. et al. Nature Medicine

Jun 2021 | FROM AKERO THERAPEUTICS

Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes

Frias, J. et al. American Diabetes Association 81st Scientific Sessions

Jun 2021 | FROM AKERO THERAPEUTICS

The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial

Loomba, R . et al. The International Liver Congress™ 2021 (EASL)

Jun 2021 | FROM AKERO THERAPEUTICS

Increased adiponectin following efruxifermin treatment is associated with improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NAS

Frias, J. et al. American Diabetes Association 81st Scientific Sessions

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline